Clinical Trial Update: VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

View source ↗

Summary

A prospective observational study to evaluate early response to vedolizumab and IL-23 antagonists in participants with Crohn's disease; the study status is recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Mirikizumab (mirikizumab)
• Risankizumab (risankizumab)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: Alimentiv Inc. | Conditions: Crohn's Disease | Status: RECRUITING